Ceritinib
ROS1 Fusion Positive
University of California, San FranciscoSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the ROS1 Fusion Positive cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Brigatinib Sameek Roychowdhury | Phase 2 | CCC |
Regorafenib University of California, San Francisco | Phase 2 | CCC |
Entrectinib Fudan University | Phase 2 | CCC |
Capmatinib University of California, San Francisco | Phase 2 | CCC |
egf816 University of California, San Francisco | Phase 2 | CC |
Same molecule, other indications
Ceritinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →